Depomed Inc (DEPO) 27.14 $DEPO
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.21 (-0.01), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)
Depomed settles patent fight Actavis over generic Gralise
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 7:46AM CDT
ACT: 295.22 (+0.69), DEPO: 27.14 (+0.65)
Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal
PR Newswire - Mon Apr 13, 7:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into a settlement agreement with Actavis, Inc. in Depomed's patent infringement litigation related to Actavis's Abbreviated New Drug Application seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlement permits Actavis to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances.
ACT: 295.22 (+0.69), DEPO: 27.14 (+0.65)
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 28.80 (+0.80), MATW: 50.74 (+0.08), ELLI: 57.00 (-0.45), SILC: 41.72 (+0.45), SGMO: 14.37 (-0.03), AFFX: 12.57 (-0.13), BABY: 41.64 (+1.71), HBIO: 6.06 (-0.29), EXAM: 42.52 (-0.16), IART: 59.75 (-0.26), SNCR: 51.87 (+0.02), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), NLNK: 53.12 (-0.07), CTRN: 24.27 (+0.16), ANAC: 66.45 (-0.22), PRSC: 49.43 (+0.42), RRGB: 80.99 (-2.02), ALOG: 87.92 (+0.38), DIOD: 28.02 (+0.12), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), ASTE: 42.80 (+0.16), DYAX: 28.12 (+0.15), FARO: 44.64 (-0.93), ECOL: 48.69 (+0.16), PFPT: 58.45 (-0.45), MTSI: 34.46 (-0.27), IRWD: 15.07 (-0.19), ABAX: 63.25 (-0.09), ANIP: 69.79 (+1.24), FORM: 9.44 (+0.05), QLGC: 15.08 (+0.44), ADUS: 27.60 (-0.33), SNHY: 40.71 (+0.16), EBIX: 29.77 (+0.86), SWHC: 14.68 (-0.12)
Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.
PR Newswire - Thu Apr 02, 3:07PM CDT
Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) oral solution to Depomed for $1.05 billion.
JNJ: 100.43 (+0.13), DEPO: 27.14 (+0.65)
Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion
PR Newswire - Thu Apr 02, 3:05PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. NUCYNTA is now the flagship asset in Depomed's growing portfolio of pain and neurology specialty pharmaceuticals. Full product labelling including Boxed Warnings for NUCYNTA ER and NUCYNTA is available at www.Nucynta.com.
DEPO: 27.14 (+0.65)
Technical Commentary on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Depomed, TherapeuticsMD, and Aoxing Pharma
PR Newswire - Thu Apr 02, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
JNJ: 100.43 (+0.13), TXMD: 7.17 (+0.01), DEPO: 27.14 (+0.65), TEVA: 63.01 (-1.15), AXN: 1.77 (+0.01)
Depomed Up 93.6% Since SmarTrend Uptrend Call (DEPO)
Comtex SmarTrend(R) - Mon Mar 23, 9:19AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 7 months, Depomed has returned 93.63% as of today's recent price of $23.89.
DEPO: 27.14 (+0.65)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 30.74 (+0.01), PMC: 28.80 (+0.80), MATW: 50.74 (+0.08), ELLI: 57.00 (-0.45), WWE: 14.19 (+0.04), SILC: 41.72 (+0.45), SGMO: 14.37 (-0.03), TRNX: 25.96 (-0.06), OFIX: 36.22 (-0.21), AFFX: 12.57 (-0.13), CHE: 122.49 (+0.25), BABY: 41.64 (+1.71), HBIO: 6.06 (-0.29), IART: 59.75 (-0.26), SONC: 30.75 (+0.14), SNCR: 51.87 (+0.02), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), NLNK: 53.12 (-0.07), ANAC: 66.45 (-0.22), XSD: 89.10 (+0.13), PRSC: 49.43 (+0.42), RRGB: 80.99 (-2.02), IPAR: 32.16 (+0.16), ALOG: 87.92 (+0.38), DIOD: 28.02 (+0.12), NSIT: 29.01 (+0.22), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), ASTE: 42.80 (+0.16), DYAX: 28.12 (+0.15), ECOL: 48.69 (+0.16), PFPT: 58.45 (-0.45), MTSI: 34.46 (-0.27), IRWD: 15.07 (-0.19), ABAX: 63.25 (-0.09), FLDM: 43.04 (-1.36), SCSS: 34.12 (+0.30), ANIP: 69.79 (+1.24), FORM: 9.44 (+0.05), BEAT: 8.82 (-0.13), QLGC: 15.08 (+0.44), ADUS: 27.60 (-0.33), PENX: 18.98 (+0.14), EBIX: 29.77 (+0.86), CORT: 6.44 (+0.38), SWHC: 14.68 (-0.12), OCFC: 16.93 (+0.01)
Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen Pharmaceuticals
PR Newswire - Tue Mar 17, 7:32AM CDT
Depomed, Inc. (Nasdaq: DEPO), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired with respect to Depomed's pending acquisition of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to completion of Depomed's previously announced financing and other customary closing conditions.
DEPO: 27.14 (+0.65)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Tue Mar 17, 6:56AM CDT
ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), CIEN: 21.97 (+0.27), AET: 107.95 (-0.41), ANAC: 66.45 (-0.22), CSL: 94.86 (+0.78), HSIC: 141.11 (+1.14), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), MCHP: 49.30 (+0.08), COLM: 60.47 (+0.21), DEPO: 27.14 (+0.65), HRL: 55.18 (+0.09), COO: 182.93 (+1.18), DYAX: 28.12 (+0.15), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), AZO: 693.41 (+2.68), EQIX: 244.78 (+1.00), KNX: 32.62 (+0.07), HAE: 42.33 (-0.21), EL: 82.42 (-0.31), FSL: 41.53 (+0.49), CCK: 54.75 (+0.19), BLL: 71.98 (-0.08), CDW: 38.93 (+0.21), ADBE: 75.50 (+0.88), AFFX: 12.57 (-0.13), AGN: 240.22 (+2.88), DPS: 78.81 (-0.38), INFA: 47.92 (-0.03), APH: 56.81 (-1.35), GEVA: 104.28 (-1.96), LII: 107.70 (+2.09), GMED: 25.09 (-0.16), BJRI: 50.54 (-1.00), DPZ: 99.80 (+0.40), HBI: 34.12 (+0.23), FL: 60.00 (-0.08), DLX: 69.57 (+0.47), ABT: 48.35 (+1.23), KR: 70.39 (-1.44), ABCO: 51.98 (-0.12), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.78 (+0.31), LEA: 116.57 (+0.28), DISH: 69.84 (+0.06), IMAX: 37.51 (+0.51), CNC: 70.90 (+0.12), CTAS: 82.05 (+0.01), CMCSA: 58.76 (-0.08), FLO: 22.50 (-0.03), BIG: 47.15 (+0.11), CRM: 67.71 (+0.33)
Deerfield Provides Debt Facility to Depomed
Business Wire - Thu Mar 12, 3:18PM CDT
Deerfield announced a $375 million debt investment in Depomed, Inc. as part of $575 million facility to support Depomed's $1.05 billion acquisition of the U.S. rights to NUCYNTA(R) from Janssen Pharmaceuticals. Depomed has announced that the Nucynta transaction will more than double its revenue base and that it is immediately accretive to earnings.
DEPO: 27.14 (+0.65)
Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition
PR Newswire - Thu Mar 12, 3:05PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement with Deerfield and Pharmakon Advisors, LP to borrow $575 million. The proceeds of the loan will be used to fund the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. which Depomed announced on January 15, 2015. Upon signing the acquisition agreement in January, Depomed placed $500 million into escrow. The escrowed amount and the proceeds of this loan will satisfy the $1.05 billion acquisition price and fees related to the transactions.
DEPO: 27.14 (+0.65)
Depomed Has Returned 98.1% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Thu Mar 12, 9:58AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQEPO) on August 11th, 2014 at $12.34. In approximately 7 months, Depomed has returned 98.06% as of today's recent price of $24.44.
DEPO: 27.14 (+0.65)
The Top Scoring Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 09, 4:48AM CDT
MNST: 139.91 (+0.06), ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), CIEN: 21.97 (+0.27), AET: 107.95 (-0.41), ANAC: 66.45 (-0.22), CSL: 94.86 (+0.78), MNK: 122.95 (-2.22), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), MCHP: 49.30 (+0.08), MYL: 72.40 (-1.67), COLM: 60.47 (+0.21), DEPO: 27.14 (+0.65), NXPI: 102.69 (+1.45), HRL: 55.18 (+0.09), NVDA: 22.31 (+0.25), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), AZO: 693.41 (+2.68), IRWD: 15.07 (-0.19), HAE: 42.33 (-0.21), EL: 82.42 (-0.31), FSL: 41.53 (+0.49), BDX: 144.33 (-1.24), F: 15.91 (+0.09), CCK: 54.75 (+0.19), BBRY: 9.92 (-0.11), OFIX: 36.22 (-0.21), NUVA: 43.38 (+0.10), CDW: 38.93 (+0.21), ADBE: 75.50 (+0.88), AGN: 240.22 (+2.88), DPS: 78.81 (-0.38), ANTM: 152.84 (-0.04), APH: 56.81 (-1.35), EXAM: 42.52 (-0.16), LII: 107.70 (+2.09), CNMD: 49.35 (+0.36), DPZ: 99.80 (+0.40), HBI: 34.12 (+0.23), ABT: 48.35 (+1.23), ABCO: 51.98 (-0.12), ORLY: 216.67 (-0.40), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.78 (+0.31), LEA: 116.57 (+0.28), IMAX: 37.51 (+0.51), CNC: 70.90 (+0.12), CTAS: 82.05 (+0.01), CMCSA: 58.76 (-0.08), FLO: 22.50 (-0.03), BIG: 47.15 (+0.11), CRM: 67.71 (+0.33)
3 Little-Known Biotech Stocks I'm Keeping an Eye On
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 07, 12:07PM CST
Source: Neuralstem. I haven't bought these three little-known biotech stocks (yet), but I am watching them closely because I think each of them could have catalysts soon that could move their shares this year. All three are small-market-cap...
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), DEPO: 27.14 (+0.65), XOMA: 3.63 (-0.04), CUR: 1.96 (-0.04)
Depomed To Present At 27th Annual Roth Conference
PR Newswire - Tue Mar 03, 7:00AM CST
Depomed, Inc. (NASDAQEPO) today announced that it will be presenting at the 27th Annual Roth Conference in Laguna Niguel, California. The presentation is scheduled for 12:30 pm ET (9:30 am PT) Tuesday, March 10, 2015.
DEPO: 27.14 (+0.65)
The Best Scoring Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Sun Mar 01, 3:33AM CST
ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), CIEN: 21.97 (+0.27), AET: 107.95 (-0.41), HSP: 87.80 (+0.04), ANAC: 66.45 (-0.22), CSL: 94.86 (+0.78), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), BCR: 175.09 (+0.24), MCHP: 49.30 (+0.08), COLM: 60.47 (+0.21), DEPO: 27.14 (+0.65), IT: 82.88 (-0.68), HRL: 55.18 (+0.09), CSX: 36.26 (+0.91), DYAX: 28.12 (+0.15), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), IRWD: 15.07 (-0.19), AZO: 693.41 (+2.68), EQIX: 244.78 (+1.00), KNX: 32.62 (+0.07), HAE: 42.33 (-0.21), FSL: 41.53 (+0.49), ACT: 295.22 (+0.69), BDX: 144.33 (-1.24), CCK: 54.75 (+0.19), BLL: 71.98 (-0.08), M: 67.00 (-0.03), CDW: 38.93 (+0.21), ADBE: 75.50 (+0.88), AFFX: 12.57 (-0.13), AGN: 240.22 (+2.88), DPS: 78.81 (-0.38), ANTM: 152.84 (-0.04), APH: 56.81 (-1.35), LII: 107.70 (+2.09), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), HBI: 34.12 (+0.23), DLX: 69.57 (+0.47), ABT: 48.35 (+1.23), ENDP: 94.09 (-1.09), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.78 (+0.31), LEA: 116.57 (+0.28), DISH: 69.84 (+0.06), IMAX: 37.51 (+0.51), IGV: 98.90 (+0.81), CTAS: 82.05 (+0.01), FLT: 158.25 (+0.01), FLO: 22.50 (-0.03), BIG: 47.15 (+0.11), CRM: 67.71 (+0.33)
Consider Depomed Long-Term For Its Specialty Expertise
Clinically Sound Investor - at Seeking Alpha - Fri Feb 27, 8:34AM CST
DEPO: 27.14 (+0.65)
Depomed (DEPO) Upgraded From Hold to Buy
at The Street - Wed Feb 25, 10:00AM CST
Depomed (DEPO) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
DEPO: 27.14 (+0.65)
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.21 (-0.01), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)
Depomed settles patent fight Actavis over generic Gralise
Seeking Alpha - at Seeking Alpha - Mon Apr 13, 7:46AM CDT
ACT: 295.22 (+0.69), DEPO: 27.14 (+0.65)
Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal
PR Newswire - Mon Apr 13, 7:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into a settlement agreement with Actavis, Inc. in Depomed's patent infringement litigation related to Actavis's Abbreviated New Drug Application seeking approval to market generic versions of Depomed's Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlement permits Actavis to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances.
ACT: 295.22 (+0.69), DEPO: 27.14 (+0.65)
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 28.80 (+0.80), MATW: 50.74 (+0.08), ELLI: 57.00 (-0.45), SILC: 41.72 (+0.45), SGMO: 14.37 (-0.03), AFFX: 12.57 (-0.13), BABY: 41.64 (+1.71), HBIO: 6.06 (-0.29), EXAM: 42.52 (-0.16), IART: 59.75 (-0.26), SNCR: 51.87 (+0.02), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), NLNK: 53.12 (-0.07), CTRN: 24.27 (+0.16), ANAC: 66.45 (-0.22), PRSC: 49.43 (+0.42), RRGB: 80.99 (-2.02), ALOG: 87.92 (+0.38), DIOD: 28.02 (+0.12), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), ASTE: 42.80 (+0.16), DYAX: 28.12 (+0.15), FARO: 44.64 (-0.93), ECOL: 48.69 (+0.16), PFPT: 58.45 (-0.45), MTSI: 34.46 (-0.27), IRWD: 15.07 (-0.19), ABAX: 63.25 (-0.09), ANIP: 69.79 (+1.24), FORM: 9.44 (+0.05), QLGC: 15.08 (+0.44), ADUS: 27.60 (-0.33), SNHY: 40.71 (+0.16), EBIX: 29.77 (+0.86), SWHC: 14.68 (-0.12)
Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.
PR Newswire - Thu Apr 02, 3:07PM CDT
Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) oral solution to Depomed for $1.05 billion.
JNJ: 100.43 (+0.13), DEPO: 27.14 (+0.65)
Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion
PR Newswire - Thu Apr 02, 3:05PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. NUCYNTA is now the flagship asset in Depomed's growing portfolio of pain and neurology specialty pharmaceuticals. Full product labelling including Boxed Warnings for NUCYNTA ER and NUCYNTA is available at www.Nucynta.com.
DEPO: 27.14 (+0.65)
Technical Commentary on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Depomed, TherapeuticsMD, and Aoxing Pharma
PR Newswire - Thu Apr 02, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
JNJ: 100.43 (+0.13), TXMD: 7.17 (+0.01), DEPO: 27.14 (+0.65), TEVA: 63.01 (-1.15), AXN: 1.77 (+0.01)
Depomed Up 93.6% Since SmarTrend Uptrend Call (DEPO)
Comtex SmarTrend(R) - Mon Mar 23, 9:19AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 7 months, Depomed has returned 93.63% as of today's recent price of $23.89. DEPO: 27.14 (+0.65)
The Best Small Cap Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Sat Mar 21, 11:24PM CDT
DMND: 30.74 (+0.01), PMC: 28.80 (+0.80), MATW: 50.74 (+0.08), ELLI: 57.00 (-0.45), WWE: 14.19 (+0.04), SILC: 41.72 (+0.45), SGMO: 14.37 (-0.03), TRNX: 25.96 (-0.06), OFIX: 36.22 (-0.21), AFFX: 12.57 (-0.13), CHE: 122.49 (+0.25), BABY: 41.64 (+1.71), HBIO: 6.06 (-0.29), IART: 59.75 (-0.26), SONC: 30.75 (+0.14), SNCR: 51.87 (+0.02), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), NLNK: 53.12 (-0.07), ANAC: 66.45 (-0.22), XSD: 89.10 (+0.13), PRSC: 49.43 (+0.42), RRGB: 80.99 (-2.02), IPAR: 32.16 (+0.16), ALOG: 87.92 (+0.38), DIOD: 28.02 (+0.12), NSIT: 29.01 (+0.22), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), ASTE: 42.80 (+0.16), DYAX: 28.12 (+0.15), ECOL: 48.69 (+0.16), PFPT: 58.45 (-0.45), MTSI: 34.46 (-0.27), IRWD: 15.07 (-0.19), ABAX: 63.25 (-0.09), FLDM: 43.04 (-1.36), SCSS: 34.12 (+0.30), ANIP: 69.79 (+1.24), FORM: 9.44 (+0.05), BEAT: 8.82 (-0.13), QLGC: 15.08 (+0.44), ADUS: 27.60 (-0.33), PENX: 18.98 (+0.14), EBIX: 29.77 (+0.86), CORT: 6.44 (+0.38), SWHC: 14.68 (-0.12), OCFC: 16.93 (+0.01)
Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen Pharmaceuticals
PR Newswire - Tue Mar 17, 7:32AM CDT
Depomed, Inc. (Nasdaq: DEPO), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired with respect to Depomed's pending acquisition of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to completion of Depomed's previously announced financing and other customary closing conditions.
DEPO: 27.14 (+0.65)
The Best Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Tue Mar 17, 6:56AM CDT
ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), CIEN: 21.97 (+0.27), AET: 107.95 (-0.41), ANAC: 66.45 (-0.22), CSL: 94.86 (+0.78), HSIC: 141.11 (+1.14), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), MCHP: 49.30 (+0.08), COLM: 60.47 (+0.21), DEPO: 27.14 (+0.65), HRL: 55.18 (+0.09), COO: 182.93 (+1.18), DYAX: 28.12 (+0.15), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), AZO: 693.41 (+2.68), EQIX: 244.78 (+1.00), KNX: 32.62 (+0.07), HAE: 42.33 (-0.21), EL: 82.42 (-0.31), FSL: 41.53 (+0.49), CCK: 54.75 (+0.19), BLL: 71.98 (-0.08), CDW: 38.93 (+0.21), ADBE: 75.50 (+0.88), AFFX: 12.57 (-0.13), AGN: 240.22 (+2.88), DPS: 78.81 (-0.38), INFA: 47.92 (-0.03), APH: 56.81 (-1.35), GEVA: 104.28 (-1.96), LII: 107.70 (+2.09), GMED: 25.09 (-0.16), BJRI: 50.54 (-1.00), DPZ: 99.80 (+0.40), HBI: 34.12 (+0.23), FL: 60.00 (-0.08), DLX: 69.57 (+0.47), ABT: 48.35 (+1.23), KR: 70.39 (-1.44), ABCO: 51.98 (-0.12), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.78 (+0.31), LEA: 116.57 (+0.28), DISH: 69.84 (+0.06), IMAX: 37.51 (+0.51), CNC: 70.90 (+0.12), CTAS: 82.05 (+0.01), CMCSA: 58.76 (-0.08), FLO: 22.50 (-0.03), BIG: 47.15 (+0.11), CRM: 67.71 (+0.33)
Deerfield Provides Debt Facility to Depomed
Business Wire - Thu Mar 12, 3:18PM CDT
Deerfield announced a $375 million debt investment in Depomed, Inc. as part of $575 million facility to support Depomed's $1.05 billion acquisition of the U.S. rights to NUCYNTA(R) from Janssen Pharmaceuticals. Depomed has announced that the Nucynta transaction will more than double its revenue base and that it is immediately accretive to earnings.
DEPO: 27.14 (+0.65)
Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition
PR Newswire - Thu Mar 12, 3:05PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement with Deerfield and Pharmakon Advisors, LP to borrow $575 million. The proceeds of the loan will be used to fund the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. which Depomed announced on January 15, 2015. Upon signing the acquisition agreement in January, Depomed placed $500 million into escrow. The escrowed amount and the proceeds of this loan will satisfy the $1.05 billion acquisition price and fees related to the transactions.
DEPO: 27.14 (+0.65)
Depomed Has Returned 98.1% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Thu Mar 12, 9:58AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 7 months, Depomed has returned 98.06% as of today's recent price of $24.44. DEPO: 27.14 (+0.65)
The Top Scoring Stocks To Buy This Week
Todd Campbell - at Seeking Alpha - Mon Mar 09, 4:48AM CDT
MNST: 139.91 (+0.06), ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), CIEN: 21.97 (+0.27), AET: 107.95 (-0.41), ANAC: 66.45 (-0.22), CSL: 94.86 (+0.78), MNK: 122.95 (-2.22), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), MCHP: 49.30 (+0.08), MYL: 72.40 (-1.67), COLM: 60.47 (+0.21), DEPO: 27.14 (+0.65), NXPI: 102.69 (+1.45), HRL: 55.18 (+0.09), NVDA: 22.31 (+0.25), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), AZO: 693.41 (+2.68), IRWD: 15.07 (-0.19), HAE: 42.33 (-0.21), EL: 82.42 (-0.31), FSL: 41.53 (+0.49), BDX: 144.33 (-1.24), F: 15.91 (+0.09), CCK: 54.75 (+0.19), BBRY: 9.92 (-0.11), OFIX: 36.22 (-0.21), NUVA: 43.38 (+0.10), CDW: 38.93 (+0.21), ADBE: 75.50 (+0.88), AGN: 240.22 (+2.88), DPS: 78.81 (-0.38), ANTM: 152.84 (-0.04), APH: 56.81 (-1.35), EXAM: 42.52 (-0.16), LII: 107.70 (+2.09), CNMD: 49.35 (+0.36), DPZ: 99.80 (+0.40), HBI: 34.12 (+0.23), ABT: 48.35 (+1.23), ABCO: 51.98 (-0.12), ORLY: 216.67 (-0.40), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.78 (+0.31), LEA: 116.57 (+0.28), IMAX: 37.51 (+0.51), CNC: 70.90 (+0.12), CTAS: 82.05 (+0.01), CMCSA: 58.76 (-0.08), FLO: 22.50 (-0.03), BIG: 47.15 (+0.11), CRM: 67.71 (+0.33)
3 Little-Known Biotech Stocks I'm Keeping an Eye On
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 07, 12:07PM CST
Source: Neuralstem. I haven't bought these three little-known biotech stocks (yet), but I am watching them closely because I think each of them could have catalysts soon that could move their shares this year. All three are small-market-cap...
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), DEPO: 27.14 (+0.65), XOMA: 3.63 (-0.04), CUR: 1.96 (-0.04)
Depomed To Present At 27th Annual Roth Conference
PR Newswire - Tue Mar 03, 7:00AM CST
Depomed, Inc. (NASDAQ
EPO) today announced that it will be presenting at the 27th Annual Roth Conference in Laguna Niguel, California. The presentation is scheduled for 12:30 pm ET (9:30 am PT) Tuesday, March 10, 2015. DEPO: 27.14 (+0.65)
The Best Scoring Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Sun Mar 01, 3:33AM CST
ELLI: 57.00 (-0.45), JCOM: 70.72 (-0.38), CAH: 91.50 (+1.15), CIEN: 21.97 (+0.27), AET: 107.95 (-0.41), HSP: 87.80 (+0.04), ANAC: 66.45 (-0.22), CSL: 94.86 (+0.78), CAVM: 73.16 (+0.39), HAS: 71.73 (-1.82), BCR: 175.09 (+0.24), MCHP: 49.30 (+0.08), COLM: 60.47 (+0.21), DEPO: 27.14 (+0.65), IT: 82.88 (-0.68), HRL: 55.18 (+0.09), CSX: 36.26 (+0.91), DYAX: 28.12 (+0.15), LVLT: 54.24 (-0.04), CBRL: 137.40 (-1.10), IRWD: 15.07 (-0.19), AZO: 693.41 (+2.68), EQIX: 244.78 (+1.00), KNX: 32.62 (+0.07), HAE: 42.33 (-0.21), FSL: 41.53 (+0.49), ACT: 295.22 (+0.69), BDX: 144.33 (-1.24), CCK: 54.75 (+0.19), BLL: 71.98 (-0.08), M: 67.00 (-0.03), CDW: 38.93 (+0.21), ADBE: 75.50 (+0.88), AFFX: 12.57 (-0.13), AGN: 240.22 (+2.88), DPS: 78.81 (-0.38), ANTM: 152.84 (-0.04), APH: 56.81 (-1.35), LII: 107.70 (+2.09), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), HBI: 34.12 (+0.23), DLX: 69.57 (+0.47), ABT: 48.35 (+1.23), ENDP: 94.09 (-1.09), DIOD: 28.02 (+0.12), LEG: 44.32 (unch), DIS: 107.94 (+0.26), GLW: 22.44 (-0.17), MAR: 80.78 (+0.31), LEA: 116.57 (+0.28), DISH: 69.84 (+0.06), IMAX: 37.51 (+0.51), IGV: 98.90 (+0.81), CTAS: 82.05 (+0.01), FLT: 158.25 (+0.01), FLO: 22.50 (-0.03), BIG: 47.15 (+0.11), CRM: 67.71 (+0.33)
Consider Depomed Long-Term For Its Specialty Expertise
Clinically Sound Investor - at Seeking Alpha - Fri Feb 27, 8:34AM CST
DEPO: 27.14 (+0.65)
Depomed (DEPO) Upgraded From Hold to Buy
at The Street - Wed Feb 25, 10:00AM CST
Depomed (DEPO) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
DEPO: 27.14 (+0.65)
